source
- Genmab reports 45.9% response rate for FRα‑directed ADC in platinum‑resistant ovarian cancer; Lilly expands Jaypirca labelGenmab presented new data on its FRα‑targeted antibody‑drug conjugate Rina‑S in patients with platinum‑resistant ovarian cancer. In the trial, the ADC achieved an objective response rate of 45.9%,…
- Roche signs $100 million upfront deal with Alector to advance Parkinson's researchRoche announced a partnership with biotech Alector focused on neuroscience and Parkinson's disease, providing an upfront cash payment of $100 million. The agreement aims to combine Roche's resourc…